Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended	6 Months Ended
	Jul. 25, 2022	Jul. 20, 2022	Jul. 18, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jun. 21, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock shares issued					48,709,652		48,511,735
Common Stock, Par Value					$ 0.001		$ 0.001
Issuance of common stock, value					$ 49		$ 49
Stock Issued During Period, Value, New Issues				$ 281,584		$ (32,490)
Proceeds from initial public offering, net of underwriting discount					0	$ 285,214
Net proceeds from sale of common stock					$ 242,900
Sale of common stock for future issuance					7,057,629
Cash, cash equivalents, and marketable securities					$ 293,600
Subsequent Event | Public offering
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock shares issued	1,250,000
Underwriting discounts and commissions	$ 15,500
Offering Costs	$ 300
Shares issued and sold	9,583,334
Net proceeds from sale of common stock	$ 242,900
Common Stock Offering Price Per Share	$ 27.00
Subsequent Event | Vertex Pharmaceuticals [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Non Refundable Upfront Payment		$ 25,000
Price Per Share			$ 23.03
Aggregate purchase price per share			$ 35,000
Public offering price per share			$ 23.03
Proceeds from initial public offering, net of underwriting discount		$ 35,000
Sale of common stock for future issuance			1,519,756
Subsequent Event | Vertex Pharmaceuticals [Member] | Strategic License and Collaboration Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Non Refundable Upfront Payment			$ 25,000
Success payments for each product			22,000
Development and commercial milestone payments under collaboration agreement			340,000
Subsequent Event | Vertex Pharmaceuticals [Member] | Maximum | Strategic License and Collaboration Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Success payments for each product			$ 66,000
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Reverse stock split					one-for-9.2595
Shares issued upon conversion of preferred stock								27,720,923